Impact BioMedical, INC. Fair Value of Long-Term Debt
Impact BioMedical, INC. (IBO) had Fair Value of Long-Term Debt of $34.70 million as of 2023-09-30, per its 10-K filed 2025-03-28.
Financial Statements › Notes › Debt Instruments
us-gaap:LongTermDebtFairValue · last filed 2025-03-28
- 2023-09-30: Long-term Debt, Fair Value $34.70M.
| Period end | Long-term Debt, Fair Value |
|---|---|
| 2023-09-30 | $34.70M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |